Overview

Most commercial RAFT agents are designed for polymerization control, including but not limited to chain length, architecture, and dispersity, and lack biologically relevant functionality for advanced drug delivery and targeting. Hence, incorporating a targeting molecule requires separate post-polymerization steps, which adds complexity and reduces reproducibility.

Researchers increasingly need reagents that pair reliable RAFT control with inherent biocompatibility and glyco‑display, enabling cellular targeting and biorecognition without sacrificing the reproducibility required for pharmaceutical development.

The Opportunity

Researchers at the Ohio State University have developed a patent-pending, saccharide‑based RAFT chain transfer agent that integrates carbohydrate functionality directly into the RAFT reagent by using protected D-galactose units as the Z‑group. To the inventors’ knowledge, this is the first reported RAFT chain transfer agent to incorporate a galactose as the Z-group rather than as a monomer. Critically, the galactose stays chemically protected during polymerization and can be deprotected afterward to expose a bioactive sugar at the polymer chain end, eliminating the need for a separate conjugation step. This creates a clearly differentiated category of biocompatible RAFT agents specifically suited for pharmaceutical and biotech teams developing next‑generation polymer therapeutics and advanced biomaterials.

The technology, currently at the proof-of-concept stage, enables the synthesis of hydrophobic, hydrophilic, and amphiphilic block copolymer systems with a desired molecular weight using standard RAFT workflows and common initiators. The resulting polymer carries carbohydrate functionality through the polymerization rather than requiring a separate conjugation step afterward.

Hydrophobic as well as hydrophilic monomers are compatible with this Gal-RAFT reagent. Additionally, resulting amphiphilic block copolymers synthesized using this RAFT reagent can self‑assemble into nanoparticles in aqueous media with tunable sizes and surface properties, which can be further adjusted by deprotecting the galactose unit, making them well-suited for drug delivery, diagnostics, and smart biomaterials. For specialty chemical and reagent suppliers, these “sugar‑RAFT” products represent a logical, higher‑margin extension to existing RAFT portfolios, enabling targeted marketing into high‑value life‑science segments such as drug delivery, diagnostics, and smart biomaterials.

Advantages

• Galactose and carboxylate functionality are built directly into the RAFT reagent, delivering glyco‑decorated, biocompatible polymers without post-polymerization modifications.
• Controlled, low-dispersity polymers and well-defined block copolymers accessible through standard RAFT workflows and common initiators.
• Self‑assembling nanoparticles with tunable size and surface charge for targeted drug delivery and sensing applications
• Direct platform for glycopolymer and functional biomaterial research, with a chemically versatile chain end for further modification.

Patents: PCT filed